Anxiety and depression stand as prevalent mental health disorders on a global scale, impacting countless individuals across all walks of life. Anxiety presents as a persistent state of apprehension, fear, and worry, often accompanied by physical manifestations like increased heart rate and trembling. Its various forms encompass generalized anxiety disorder, panic disorder, social anxiety disorder, and specific phobias. Conversely, depression manifests through enduring feelings of sadness, hopelessness, and disinterest in once-enjoyable activities, alongside physical symptoms such as changes in appetite and sleep patterns, fatigue, and difficulty concentrating. Major depressive disorder and persistent depressive disorder represent common iterations, significantly impeding daily functioning and life quality. Frequently, individuals grapple with both anxiety and depression concurrently, termed comorbid anxiety-depression. The etiology of these conditions is intricate, involving genetic predispositions, environmental stressors, and psychological factors. Traumatic experiences, chronic stress, neurotransmitter imbalances, and genetic predispositions all contribute to their development. Treatment strategies typically encompass a blend of therapy, medication, and lifestyle adjustments. Cognitive-behavioral therapy (CBT) and other psychotherapeutic modalities empower individuals to comprehend and regulate their thoughts and behaviors. Pharmacological interventions, including antidepressants and anti-anxiety medications, serve to mitigate symptoms. Furthermore, lifestyle modifications such as regular exercise, balanced nutrition, ample sleep, and stress management techniques constitute integral facets of a holistic treatment regimen. Timely intervention and sustained support are paramount in effectively managing anxiety and depression, thereby fostering improved overall well-being.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States